SEARCH:   Advanced

Blood, 15 June 2006, Vol. 107, No. 12, pp. 4643-4649. Prepublished online as a Blood First Edition Paper on February 21, 2006; DOI 10.1182/blood-2005-11-4659. This Article Full Text (PDF) All Versions of this Article: 2005-11-4659v1 107/12/4643    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Arcaini, L. Articles by Iannitto, E. Search for Related Content PubMed PubMed Citation Articles by Arcaini, L. Articles by Iannitto, E. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 28, 2005 Accepted February 3, 2006 Splenic marginal zone lymphoma: a prognostic model for clinical use Luca Arcaini*, Mario Lazzarino, Nora Colombo, Sara Burcheri, Emanuela Boveri, Marco Paulli, Enrica Morra, Marcello Gambacorta, Sergio Cortelazzo, Alessandra Tucci, Marco Ungari, Achille Ambrosetti, Fabio Menestrina, Lorella Orsucci, Domenico Novero, Alessandro Pulsoni, Maurizio Frezzato, Gianluca Gaidano, Daniele Vallisa, Viviana Minardi, Claudio Tripodo, Vincenzo Callea, Luca Baldini, Francesco Merli, Massimo Federico, Vito Franco, and Emilio Iannitto Divisions of Hematology and Pathology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy Divisions of Hematology and Pathology, Ospedale Niguarda Ca' Granda, Milano, Italy Division of Hematology, Ospedali Riuniti, Bergamo, Italy Ospedali Civili, Divisions of Hematology and Pathology, Brescia, Italy Departments of Clinical and Experimental Medicine and of Pathology, University of Verona, Verona, Italy Divisions of Hematology and Pathology, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy Department of Hematology, University "La Sapienza", Roma, Italy Division of Hematology, Ospedale S. Bortolo, Vicenza, Italy Division of Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy Division of Medicine and Hematology, Ospedale G. da Saliceto, Piacenza, Italy Divisions of Hematology and Pathology, University of Palermo, Palermo, Italy Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy Department of Hematology, IRCCS Ospedale Maggiore, University of Milano, Milano, Italy Division of Hematology, Ospedale S.Maria Nuova, Reggio Emilia, Italy Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy * Corresponding author; email: luca.arcaini{at}unipv.it. The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcome of splenic marginal zone lymphoma and to identify prognostic factors. We studied 309 patients: the 5-years cause-specific survival (CSS) was 76%. In univariate analysis the parameters predictive of shorter CSS were hemoglobin < 12 g/dl (p=0.00002), albumin < 3.5 g/dl (p=0.001), IPI 2-3 (p=0.00001), LDH >normal (p=0.00001), age >60 years (p=0.01), platelets < 100,000/ml (p=0.04), HbsAg-positivity (p=0.01), no splenectomy at diagnosis (p=0.006). Hemoglobin < 12 g/dl, LDH >normal, albumin < 3.5 g/dl maintained a negative influence on CSS in multivariate analysis. Using these 3 variables, we identified 3 prognostic categories: low-risk group (41%) with no adverse factors, intermediate-risk group (34%) with one factor, high-risk group (25%) with 2 or 3 factors. The 5-years CSS was 88% for the low-risk, 73% for the intermediate-risk, and 50% for the high-risk group. The cause-specific mortality rate (x1000 p-yrs) was 20 for the low-risk, 47 for the intermediate-risk, and 174 for the high-risk group. This latter group accounted for 54% of all lymphoma-related deaths. In conclusion, using readily available factors, this prognostic index may be a useful tool for evaluating the need for treatment as well as the intensity of therapy in an individual patient. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Cervetti, S. Galimberti, E. Sordi, G. Buda, E. Orciuolo, N. Cecconi, and M. Petrini Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL) Ann. Onc., October 13, 2009; (2009) mdp395v1. [Abstract] [Full Text] [PDF] C. KALPADAKIS, G. A. PANGALIS, E. DIMITRIADOU, M. K. ANGELOPOULOU, M. P. SIAKANTARIS, M.-C. KYRTSONIS, M. XIMERIS, T. TZENOU, S. SAHANAS, X. YIAKOUMIS, et al. Mutation Analysis of IgVH Genes in Splenic Marginal Zone Lymphomas: Correlation with Clinical Characteristics and Outcome Anticancer Res, May 1, 2009; 29(5): 1811 - 1816. [Abstract] [Full Text] [PDF] E. Boveri, L. Arcaini, M. Merli, F. Passamonti, S. Rizzi, L. Vanelli, E. Rumi, S. Rattotti, M. Lucioni, C. Picone, et al. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients Ann. Onc., January 1, 2009; 20(1): 129 - 136. [Abstract] [Full Text] [PDF] J. S. Abramson, M. Chatterji, and A. Rahemtullah Case 39-2008 -- A 51-Year-Old Woman with Splenomegaly and Anemia N. Engl. J. Med., December 18, 2008; 359(25): 2707 - 2718. [Full Text] [PDF] B. Kahl and D. Yang Marginal Zone Lymphomas: Management of Nodal, Splenic, and MALT NHL Hematology, January 1, 2008; 2008(1): 359 - 364. [Abstract] [Full Text] [PDF] L Arcaini, S Burcheri, A Rossi, M Paulli, R Bruno, F Passamonti, E Brusamolino, A Molteni, A Pulsoni, M. Cox, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT Ann. Onc., February 1, 2007; 18(2): 346 - 350. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020